XT
SMMT icon

XTX Topco’s Summit Therapeutics SMMT Stock Holding History

XTX Topco’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,535
Closed -$300K – 3757
2025
Q3 		$300K Sell
14,535
-28,913
-67% -$701K 0.02% 1504
2025
Q2 		$925K Buy
+43,448
New +$991K 0.04% 713
2024
Q4 		– Sell
-23,915
Closed -$524K – 2887
2024
Q3 		$524K Buy
23,915
+8,415
+54% +$118K 0.04% 785
2024
Q2 		$121K Buy
+15,500
New +$83.7K 0.01% 1375
2023
Q2 		– Sell
-27,013
Closed -$47.3K – 1801
2023
Q1 		$47.3K Buy
+27,013
New +$73.7K 0.01% 1172

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PCMH
Polymer Capital Management (HK) Hong Kong $1.16B AUM 135.84% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

XTX Topco's SMMT Position: Q4 2025 in Review

XTX Topco sold out of Summit Therapeutics (SMMT) in Q4 2025, closing a stake of 14,535 shares — an estimated $300K sold.

XTX Topco first reported a position in SMMT in Q1 2023 and held it in 5 quarters. The position peaked at $925K in Q2 2025. 206 funds tracked by Wall St. Rank hold SMMT as of Q4 2025.

  • XTX Topco reported no remaining Summit Therapeutics position as of Q4 2025 after selling out during the quarter.
  • XTX Topco sold 14,535 Summit Therapeutics shares in Q4 2025, an estimated $300K.
  • XTX Topco first reported a position in Summit Therapeutics in Q1 2023 and held it in 5 quarters.
  • XTX Topco's Summit Therapeutics position peaked at $925K in Q2 2025.
  • 206 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2025.

Based on XTX Topco's 13F filing for Q4 2025, filed 17 Feb 2026.